 Connection
Prem Subramanian to Diplopia
This is a "connection" page, showing publications Prem Subramanian has written about Diplopia.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.535 |
|
|
|
-
Bou Ghannam A, Subramanian PS. Delayed Onset Cranial Nerve Palsies After Endovascular Coil Embolization of Direct Carotid-Cavernous Fistulas. J Neuroophthalmol. 2018 06; 38(2):156-159.
Score: 0.616
-
Cruz FM, Blitz AM, Subramanian PS. Partial third nerve palsy and ocular neuromyotonia from displacement of posterior communicating artery detected by high-resolution MRI. J Neuroophthalmol. 2013 Sep; 33(3):263-5.
Score: 0.443
-
Subramanian PS, Cho RI, Kahana A. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr Opin Ophthalmol. 2023 Nov 01; 34(6):487-492.
Score: 0.221
-
Tamhankar MA, Biousse V, Ying GS, Prasad S, Subramanian PS, Lee MS, Eggenberger E, Moss HE, Pineles S, Bennett J, Osborne B, Volpe NJ, Liu GT, Bruce BB, Newman NJ, Galetta SL, Balcer LJ. Isolated third, fourth, and sixth cranial nerve palsies from presumed microvascular versus other causes: a prospective study. Ophthalmology. 2013 Nov; 120(11):2264-9.
Score: 0.109
-
Wu-Chen WY, Christoff A, Subramanian PS, Eggenberger ER. Diplopia and quality of life. Ophthalmology. 2011 Jul; 118(7):1481-1481.e2.
Score: 0.095
-
Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, Qadeer RA, Cameron C. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison. JAMA Ophthalmol. 2022 04 01; 140(4):328-335.
Score: 0.050
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|